临床试验/IRCT20180416039318N2

IRCT20180416039318N2招募中3 期

Assessing the preventing and therapeutic effect of curcumin in radiotherapy-induced mucositis of head and neck cancers

Mashhad University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新: 2018年6月18日

适应症

试验速览

阶段: 3 期
状态: 招募中
发起方: Mashhad University of Medical Sciences
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 no limit（—）
性别: All

入选标准

•Inclusion criteria were the following: minimum age of 18 years, presence of head and neck cancer, radiationtherapy of 50 Gy or greater, at least 50% of patient’s oral cavity in the field of radiation, and willing to be a part of the study and sign the informed consent..

排除标准

•Exclusion criteria were the following: the history of previous radiation therapy or chemotherapy, chemotherapy protocol in addition to radiotherapy, any allergy to condiments, especially Turmeric root”, having a pre-existing oral disease such as an active oral infection or an oral ulceration.

研究者

发起方

Mashhad University of Medical Sciences

相似试验

Study on the preventive and therapeutic effect of Cordyceps militaris on patients with chronic obstructive pulmonary disease and insulin resistance based on gut microbiotachronic obstructive pulmonary disease

ITMCTR2000003781Shanghai Sixth People's Hospital East Campus

Itolizumab (T1h) combined with insulin in patients with Type I Diabetes MellitusDiabetes Mellitus, Type 1Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesDiabetes MellitusType 1 diabetes mellitus

RPCEC00000225Center of Molecular Immunology (CIM)40

VALERGEN-combination of routes- Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental Illness

RPCEC00000298ational Center of Bioproducts (BioCen)180

进行中（未招募）

Study of the efficacy and safety of Lcr Regenerans®_GynoCans.

EUCTR2013-002480-26-PLBIOSE234

进行中（未招募）

Study of the efficacy and safety of treatment administered intravaginallyin the treatment of bacterial vaginosis.MedDRA version: 19.0Level: LLTClassification code 10046960Term: Vaginosis bacterialSystem Organ Class: 100000004862Bacterial vaginosis

EUCTR2015-004563-37-PLaboratoires IPRAD PHARMA530